INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME

The aim of present study was to evaluate safety and clinical efficacy of inhalatory immunotherapy based on intranasal delivery of bioactive factors produced by M2 macrophages applied for treatment of patients with organic brain syndrome (OBS).Materials and methods. The study under the NCT02957123 pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. A. Ostanin, M. N. Davydova, N. M. Starostina, L. V. Sakhno, E. Ya. Shevela, E. R. Chernykh
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2018
Materias:	m2 type macrophages cytokines intranasal inhalations functional recovery organic brain syndrome Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/31c6d3581cc745bdb74b5ca50c7880a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31c6d3581cc745bdb74b5ca50c7880a7
record_format	dspace
spelling	oai:doaj.org-article:31c6d3581cc745bdb74b5ca50c7880a72021-11-18T08:03:47ZINTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME1563-06252313-741X10.15789/1563-0625-2018-4-577-588https://doaj.org/article/31c6d3581cc745bdb74b5ca50c7880a72018-06-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1566https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe aim of present study was to evaluate safety and clinical efficacy of inhalatory immunotherapy based on intranasal delivery of bioactive factors produced by M2 macrophages applied for treatment of patients with organic brain syndrome (OBS).Materials and methods. The study under the NCT02957123 protocol (www.ClinicalTrails.gov) included thirty patients with OBS of various genesis (10 men and 20 women aged 18 to 81; Me, 62.5 years). Neurological assessment and the levels of 32 cytokines in the blood serum of patients were evaluated before and 2-3 days after completion of inhalation immunotherapy.Intranasal inhalations of cell-free culture medium of M2 macrophages (2 mL, once a day for 28-30 days) were safe and well tolerated. None of 30 treated patients had severe adverse events and serious treatmentrelated side reactions. One month after starting the inhalations, a positive dynamics in neurological status was noted in all the patients. A marked clinical response was documented in twenty out of thirty patients (67%), which manifested as improvement, according to all scales and questionnaires. The neurological improvement was not reversed over 6 months of follow-up period. In other ten patients (33%), a moderate clinical response was shown as improvement of individual scores. The positive changes were as follows: 1) a 43% decrease in anxiety and depression scores (according to HADS scale, pU = 0.0008); 2) an increase of total motor activity (stability and gait) by 25%, pU = 0.0001); 3) correction of cognitive functions (MoCa test, pU = 0.007); 4) reduced number and intensity of the disease symptoms by 52% (pU = 0.0001). This marked clinical response to immunotherapy is shown to be associated with correction/normalization of serum hepatocyte growth factor (HGF) level.Conclusion. Inhalation immunotherapy based on intranasal delivery of bioactive factors produced by M2 macrophages can improve neurological and functional recovery in patients with organic brain syndrome.A. A. OstaninM. N. DavydovaN. M. StarostinaL. V. SakhnoE. Ya. ShevelaE. R. ChernykhSPb RAACIarticlem2 type macrophagescytokinesintranasal inhalationsfunctional recoveryorganic brain syndromeImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 20, Iss 4, Pp 577-588 (2018)
institution	DOAJ
collection	DOAJ
language	RU
topic	m2 type macrophages cytokines intranasal inhalations functional recovery organic brain syndrome Immunologic diseases. Allergy RC581-607
spellingShingle	m2 type macrophages cytokines intranasal inhalations functional recovery organic brain syndrome Immunologic diseases. Allergy RC581-607 A. A. Ostanin M. N. Davydova N. M. Starostina L. V. Sakhno E. Ya. Shevela E. R. Chernykh INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME
description	The aim of present study was to evaluate safety and clinical efficacy of inhalatory immunotherapy based on intranasal delivery of bioactive factors produced by M2 macrophages applied for treatment of patients with organic brain syndrome (OBS).Materials and methods. The study under the NCT02957123 protocol (www.ClinicalTrails.gov) included thirty patients with OBS of various genesis (10 men and 20 women aged 18 to 81; Me, 62.5 years). Neurological assessment and the levels of 32 cytokines in the blood serum of patients were evaluated before and 2-3 days after completion of inhalation immunotherapy.Intranasal inhalations of cell-free culture medium of M2 macrophages (2 mL, once a day for 28-30 days) were safe and well tolerated. None of 30 treated patients had severe adverse events and serious treatmentrelated side reactions. One month after starting the inhalations, a positive dynamics in neurological status was noted in all the patients. A marked clinical response was documented in twenty out of thirty patients (67%), which manifested as improvement, according to all scales and questionnaires. The neurological improvement was not reversed over 6 months of follow-up period. In other ten patients (33%), a moderate clinical response was shown as improvement of individual scores. The positive changes were as follows: 1) a 43% decrease in anxiety and depression scores (according to HADS scale, pU = 0.0008); 2) an increase of total motor activity (stability and gait) by 25%, pU = 0.0001); 3) correction of cognitive functions (MoCa test, pU = 0.007); 4) reduced number and intensity of the disease symptoms by 52% (pU = 0.0001). This marked clinical response to immunotherapy is shown to be associated with correction/normalization of serum hepatocyte growth factor (HGF) level.Conclusion. Inhalation immunotherapy based on intranasal delivery of bioactive factors produced by M2 macrophages can improve neurological and functional recovery in patients with organic brain syndrome.
format	article
author	A. A. Ostanin M. N. Davydova N. M. Starostina L. V. Sakhno E. Ya. Shevela E. R. Chernykh
author_facet	A. A. Ostanin M. N. Davydova N. M. Starostina L. V. Sakhno E. Ya. Shevela E. R. Chernykh
author_sort	A. A. Ostanin
title	INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME
title_short	INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME
title_full	INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME
title_fullStr	INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME
title_full_unstemmed	INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME
title_sort	intranasal inhalations of bioactive factors produced by m2 macrophages in the treatment of patients with organic brain syndrome
publisher	SPb RAACI
publishDate	2018
url	https://doaj.org/article/31c6d3581cc745bdb74b5ca50c7880a7
work_keys_str_mv	AT aaostanin intranasalinhalationsofbioactivefactorsproducedbym2macrophagesinthetreatmentofpatientswithorganicbrainsyndrome AT mndavydova intranasalinhalationsofbioactivefactorsproducedbym2macrophagesinthetreatmentofpatientswithorganicbrainsyndrome AT nmstarostina intranasalinhalationsofbioactivefactorsproducedbym2macrophagesinthetreatmentofpatientswithorganicbrainsyndrome AT lvsakhno intranasalinhalationsofbioactivefactorsproducedbym2macrophagesinthetreatmentofpatientswithorganicbrainsyndrome AT eyashevela intranasalinhalationsofbioactivefactorsproducedbym2macrophagesinthetreatmentofpatientswithorganicbrainsyndrome AT erchernykh intranasalinhalationsofbioactivefactorsproducedbym2macrophagesinthetreatmentofpatientswithorganicbrainsyndrome
_version_	1718422341358190592

INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME

Ejemplares similares